Enterprise Value
36.62B
Cash
1.074B
Avg Qtr Burn
N/A
Short % of Float
2.50%
Insider Ownership
0.16%
Institutional Own.
92.95%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QALSODY™ BIIB067 (tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
Leqembi (Lecanemab) (Aβ mAb) Details Alzheimer's disease | Approved Quarterly sales | |
ZURZUVAE BIIB125 (zuranolone) Details Postpartum depression | Approved Quarterly sales | |
ADUHELM™ / Aducanumab (Aβ mAb) Details Alzheimer’s disease | Approved Quarterly sales | |
TOFIDENCE (BIIB800) (tocilizumab) Details Polyarticular juvenile idiopathic arthritis, Rheumatoid arthritis | Approved Quarterly sales | |
SKYCLARYS™ (Omavaloxolone) Details Friedreich’s Ataxia | Approved Quarterly sales | |
Leqembi (Lecanemab) IV Maintenance Dosing Details Alzheimer's disease | PDUFA Approval decision | |
Leqembi (Lecanemab) SC formulation Details Alzheimer's disease | BLA Acceptance for review | |
Dapirolizumab pegol Details Systemic lupus erythematosus | Phase 3 Data readout | |
BIIB124 Details Essential tremor | Phase 2b Data readout | |
BIIB080 (tau ASO) Details Alzheimer's disease | Phase 2 Data readout | |
IONS582 /BIIB121 Details Angelman Syndrome | Phase 1b Data readout | |
BIIB113 Details Alzheimer's disease | Phase 1 Update | |
BIIB093 (IV glibenclamide) Details Acute myocardial infarction | Failed Discontinued | |
SB15 (biosimilar referencing EYLEA®) Details no known indication | Failed Discontinued | |
BIIB074 (vixotrigine) Details no known indication | Failed Discontinued | |
ATXN2 ASO (BIIB105) Details Amyotrophic lateral sclerosis | Failed Discontinued |